CLE-HM29A-100μg / 询价
CLE-HM29A-500μg / 询价
CLE-HM29A-500μgx2 / 询价
- 客服电话
- 技术支持
Human CLEC9A Protein
Recombinant Human CLEC9A Protein is expressed from HEK293 with hFc tag at the N-Terminus.It contains Lys57-Val241 [Accession | Q6UXN8].
The protein has a predicted MW of 48.5 kDa. Due to glycosylation, the protein migrates to 55-65 kDa based on Bis-Tris PAGE result.
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC
Less than 1EU per μg by the LAL method.
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Human CLEC9A on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Human CLEC9A is greater than 95% as determined by SEC-HPLC.
Immobilized Human CLEC9A, hFc Tag at 0.5μg/ml (100μl/Well) on the plate. Dose response curve for Biotinylated Anti-CLEC9A Antibody, hFc Tag with the EC50 of 5.9ng/ml determined by ELISA.
CLEC9A is a recently discovered C-type lectin receptor involved in sensing necrotic cells. In humans, this receptor is selectively expressed by BDCA3(+) myeloid dendritic cells (mDCs), which have been proposed to be the main human cross-presenting mDCs and may represent the human homologue of murine CD8(+) DCs. In mice, it was demonstrated that antigens delivered with antibodies to CLEC9A are presented by CD8(+) DCs to both CD4(+) and CD8(+) T cells and induce antitumor immunity in a melanoma model.
CD370; CLEC9A; 9830005G06Rik; DNGR-1; HEEE9341; UNQ9341
(1) Schreibelt G, Klinkenberg LJ, Cruz LJ, Tacken PJ, Tel J, Kreutz M, Adema GJ, Brown GD, Figdor CG, de Vries IJ. The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells. Blood. 2012 Mar 8;119(10):2284-92. doi: 10.1182/blood-2011-08-373944. Epub 2012 Jan 10. PMID: 22234694.
